{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:26:56Z","timestamp":1793320016499,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003248","name":"Ontario Mental Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.neuropharm.2019.05.011","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T07:44:14Z","timestamp":1557387854000},"page":"107634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Insight and medication adherence in schizophrenia: An analysis of the CATIE trial"],"prefix":"10.1016","volume":"168","author":[{"given":"Julia","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miracle","family":"Ozzoude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-4963","authenticated-orcid":false,"given":"Fernando","family":"Caravaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Graff-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gerretsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.05.011_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the calgary depression scale","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatr. Suppl."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1447-0349.2010.00681.x","article-title":"An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia","volume":"19","author":"Anderson","year":"2010","journal-title":"Int. J. Ment. Health Nurs."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib4","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.4088\/JCP.v67n0715","article-title":"A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","article-title":"Subjective response to neuroleptics in schizophrenia","volume":"19","author":"Awad","year":"1993","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0920-9964(03)00189-0","article-title":"A new instrument for measuring insight: the Beck Cognitive Insight Scale","volume":"68","author":"Beck","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2014.03.029","article-title":"Insight facilitation with add-on tDCS in schizophrenia","volume":"156","author":"Bose","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00023210-200721020-00004","article-title":"Lack of insight in schizophrenia: impact on treatment adherence","volume":"21","author":"Buckley","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib10","first-page":"28","article-title":"The clinical global impressions scale","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry Edgmont"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.4088\/JCP.v66n0806","article-title":"A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder","volume":"66","author":"Byerly","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyy074","article-title":"The effects of add-on fronto-temporal transcranial direct current stimulation (tDCS) on auditory verbal hallucinations, other psychopathological symptoms and insight in schizophrenia: a randomized, double-blind, sham-controlled trial","author":"Chang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2018.12.052","article-title":"Enhancement of cognitive insight and higher-order neurocognitive function by fronto-temporal transcranial direct current stimulation (tDCS) in patients with schizophrenia","author":"Chang","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","article-title":"Medication adherence of individuals with a first episode of psychosis","volume":"106","author":"Coldham","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib15","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.euroneuro.2015.04.003","article-title":"Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies","volume":"25","author":"Czobor","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/hbm.21490","article-title":"Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia","volume":"34","author":"Gerretsen","year":"2013","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2014.10.015","article-title":"Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivity","volume":"160","author":"Gerretsen","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/hbm.22624","article-title":"Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance","volume":"36","author":"Gerretsen","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1192\/bjp.bp.105.019489","article-title":"Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial","volume":"189","author":"Gray","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib20","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0035-1555939","article-title":"Clozapine prescription and quality of life in Chinese patients with schizophrenia treated in primary care","volume":"48","author":"Hou","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib26","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(95)00018-6","article-title":"Insight in schizophrenia and its relationship to psychopathology","volume":"18","author":"Kemp","year":"1995","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/bmj.312.7027.345","article-title":"Compliance therapy in psychotic patients: randomised controlled trial","volume":"312","author":"Kemp","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1192\/bjp.172.5.413","article-title":"Randomised controlled trial of compliance therapy. 18-month follow-up","volume":"172","author":"Kemp","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0193945902238836","article-title":"Lack of awareness and nonadherence in schizophrenia","volume":"25","author":"Kozuki","year":"2003","journal-title":"West. J. Nurs. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brat.2014.11.008","article-title":"Metacognitive training (MCT) for schizophrenia improves cognitive insight: a randomized controlled trial in a Chinese sample with schizophrenia spectrum disorders","volume":"64","author":"Lam","year":"2015","journal-title":"Behav. Res. Ther."},{"issue":"Suppl. 5","key":"10.1016\/j.neuropharm.2019.05.011_bib34","first-page":"3","article-title":"Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib35","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/schbul\/sbm002","article-title":"Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review","volume":"33","author":"Lincoln","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/oxfordjournals.schbul.a006898","article-title":"A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years","volume":"27","author":"Linden","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2013.05.025","article-title":"Depression and insight in schizophrenia: comparisons of levels of deficits in social cognition and metacognition and internalized stigma across three profiles","volume":"148","author":"Lysaker","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/wps.20508","article-title":"Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments","volume":"17","author":"Lysaker","year":"2018","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2016.10.004","article-title":"The impact of second generation antipsychotics on insight in schizophrenia: results from 14 randomized, placebo controlled trials","volume":"27","author":"Mattila","year":"2017","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0920-9964(02)00316-X","article-title":"Insight in schizophrenia: a meta-analysis","volume":"61","author":"Mintz","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0920-9964(03)00047-1","article-title":"Insight in early psychosis: a 1-year follow-up","volume":"67","author":"Mintz","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib42","doi-asserted-by":"crossref","first-page":"e1130","DOI":"10.4088\/JCP.15m10115","article-title":"Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset","volume":"77","author":"Misdrahi","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/schbul\/sbn067","article-title":"Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia","volume":"35","author":"Mohamed","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.0001-690X.2003.00193.x","article-title":"Clinical correlates of early medication adherence: West London first episode schizophrenia study","volume":"108","author":"Mutsatsa","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib46","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1017\/S0033291716003421","article-title":"Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis","volume":"47","author":"Ochoa","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1176\/appi.ps.57.2.205","article-title":"Awareness of illness and nonadherence to antipsychotic medications among persons with schizophrenia","volume":"57","author":"Olfson","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pnpbp.2018.08.033","article-title":"The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: an analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data","volume":"89","author":"Ozzoude","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib49","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/bmj.327.7419.834","article-title":"Compliance therapy: a randomised controlled trial in schizophrenia","volume":"327","author":"O'Donnell","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/070674370905400106","article-title":"Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis","volume":"54","author":"Rabinovitch","year":"2009","journal-title":"Can. J. Psychiatry Rev. Can. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","article-title":"The use of electronic monitoring (MEMS\u00ae) to evaluate antipsychotic compliance in outpatients with schizophrenia","volume":"90","author":"Remington","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/JCP.0b013e31828568bc","article-title":"Examining levels of antipsychotic adherence to better understand nonadherence","volume":"33","author":"Remington","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","article-title":"Long-acting risperidone and oral antipsychotics in unstable schizophrenia","volume":"364","author":"Rosenheck","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.nmd.0000130137.85640.70","article-title":"Insight in relation to psychosocial adjustment in schizophrenia","volume":"192","author":"Simon","year":"2004","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/026988110101500209","article-title":"Suicide and schizophrenia","volume":"15","author":"Siris","year":"2001","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.scog.2015.05.002","article-title":"Insight and subjective measures of quality of life in chronic schizophrenia","volume":"2","author":"Siu","year":"2015","journal-title":"Schizophr Res Cogn"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0022-3956(03)00091-8","article-title":"Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients","volume":"38","author":"Smith","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajp.2018.08.008","article-title":"High-definition transcranial direct current simulation (HD-tDCS) for persistent auditory hallucinations in schizophrenia","volume":"37","author":"Sreeraj","year":"2018","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ps.52.6.805","article-title":"Using drug claims data to assess the relationship of medication adherence with hospitalization and costs","volume":"52","author":"Svarstad","year":"2001","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1192\/bjp.182.2.123","article-title":"Predicting engagement with services for psychosis: insight, symptoms and recovery style","volume":"182","author":"Tait","year":"2003","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib62","first-page":"53","article-title":"Interrater reliability issues in multicenter trials, Part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394","volume":"33","author":"Tracy","year":"1997","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib64","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.neubiorev.2009.12.004","article-title":"Self-reflection and the brain: a theoretical review and meta-analysis of neuroimaging studies with implications for schizophrenia","volume":"34","author":"van der Meer","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.05.011_bib65","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1176\/ps.2007.58.9.1187","article-title":"Relationships among subjective and objective measures of adherence to oral antipsychotic medications","volume":"58","author":"Velligan","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2019.05.011_bib66","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib67","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.neuropharm.2019.05.011_bib68","series-title":"WRAT-3\u202f: Wide Range Achievement Test Administration Manual","author":"Wilkinson","year":"1993"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819301613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:07:06Z","timestamp":1758438426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819301613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":66,"alternative-id":["S0028390819301613"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insight and medication adherence in schizophrenia: An analysis of the CATIE trial","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107634"}}